X
CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19). Learn More

Goserelin (Zoladex®)

Common name: Goserelin
Brand name: Zoladex®
 

What is Goserelin?

Goserelin is a hormonal therapy used to treat advanced prostate cancer by blocking the production or action of luteinizing hormone releasing hormone (LHRH) which reduces the levels of testosterone in the body.

Goserelin is used:
  • in the palliative treatment of patients with hormone-dependent advanced prostate cancer.
  • in combination with non-steroidal anti-androgens and radiation therapy for treating locally advanced prostate cancer.
  • as an adjuvant hormone therapy to external beam irradiation for locally advanced prostate cancer.


How is Goserelin administered?

Goserelin is administered by subcutaneous injection.


What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received goserelin. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast tenderness
  • Changes to mood
  • Decreased sex drive (low libido)
  • Fatigue
  • Hot flashes
  • Impotence
  • Nausea / vomiting
  • Osteoporosis (weakened bones)
  • Rashes
  • Sore joints
  • Weight gain
 

Is Goserelin covered in my province or territory?

Goserelin is covered by all provincial/territorial drug programs.
 
Last Reviewed: July 2017
Prostate Cancer Canada and Canadian Cancer Society








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.
More

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More


Click here for news archive